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Accumulating evidence has shown a strong relationship between Alzheimer’s disease (AD),
cerebral amyloid angiopathy (CAA), and cerebrovascular disease. Cognitive impairment in
AD patients can result from cortical microinfarcts associated with CAA, as well as the
synaptic and neuronal disturbances caused by cerebral accumulations of β-amyloid (Aβ)
and tau proteins.The pathophysiology of AD may lead to a toxic chain of events consisting
of Aβ overproduction, impaired Aβ clearance, and brain ischemia. Insufficient removal of
Aβ leads to development of CAA and plays a crucial role in sporadic AD cases, implicating
promotion of Aβ clearance as an important therapeutic strategy. Aβ is mainly eliminated by
three mechanisms: (1) enzymatic/glial degradation, (2) transcytotic delivery, and (3) perivas-
cular drainage (3-“d” mechanisms). Enzymatic degradation may be facilitated by activation
of Aβ-degrading enzymes such as neprilysin, angiotensin-converting enzyme, and insulin-
degrading enzyme. Transcytotic delivery can be promoted by inhibition of the receptor for
advanced glycation end products (RAGE), which mediates transcytotic influx of circulating
Aβ into brain. Successful use of the RAGE inhibitor TTP488 in Phase II testing has led to a
Phase III clinical trial for AD patients.The perivascular drainage system seems to be driven
by motive force generated by cerebral arterial pulsations, suggesting that vasoactive drugs
can facilitate Aβ clearance. One of the drugs promoting this system is cilostazol, a selec-
tive inhibitor of type 3 phosphodiesterase. The clearance of fluorescent soluble Aβ tracers
was significantly enhanced in cilostazol-treated CAA model mice. Given that the balance
between Aβ synthesis and clearance determines brain Aβ accumulation, and that Aβ is
cleared by several pathways stated above, multi-drugs combination therapy could provide
a mainstream cure for sporadic AD.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of demen-
tia in the elderly. AD is pathologically characterized by β-amyloid
(Aβ) plaques within the brain parenchyma and Aβ accumulation
in blood vessels (cerebral amyloid angiopathy; CAA), as well as by
the formation of neurofibrillary tangles and neurodegeneration
(Duyckaerts et al., 2009). AD was not previously thought to be
closely linked to cerebrovascular disease (CVD), but accumulating
lines of evidence have shown a strong relationship between AD and
vascular dementia (VaD) (Fotuhi et al., 2009; Kalaria and Ihara,
2013). AD and CVD share common risk factors (Viswanathan
et al., 2009; Kalaria et al., 2012), and treatment of vascular risk
factors is associated with slower decline in cognitive impairments
of AD patients (Deschaintre et al., 2009). The Nun study revealed
that CVD plays an important role in determining the presence and
severity of the clinical symptoms of AD (Snowdon et al., 1997).
Aβ accumulation and other AD changes are also recognized in
elderly patients without apparent dementia (Funato et al., 1998;
Schneider et al., 2007), which implies a strong relationship between
AD neuropathology and the aging processes. Many reports have
described that a majority of sporadic dementia patients have a
mixture of AD and CVD pathology (Neuropathology Group of
Medical Research Council Cognitive Function and Aging Study
(MRC CFAS), 2001; Toledo et al., 2013). Hemorrhage, infarctions,
and vascular changes are not specific indicators for VaD.
Cerebral amyloid angiopathy often induces lobar hemorrhage
and cortical microhemorrhage, which mainly affects the occip-
ital lobe (Charidimou et al., 2012). In addition, imaging tech-
nology advances, including 7 T MRI, have identified numerous
cortical microinfarcts (CMI), which have been attributed to CAA
(Suter et al., 2002; van Veluw et al., 2013; Westover et al., 2013).
Cognitive impairment in AD patients may result from hypoper-
fusion/ischemia and CMIs, as well as synaptic disturbance and
neuronal loss caused by Aβ and tau accumulation (Okamoto
et al., 2009; Launer et al., 2011; Smith et al., 2012). Small ves-
sel injury is frequent in both AD and VaD. CAA was previously
thought to be pathologically different from Binswanger disease,
one of the common forms of VaD characterized by arterioloscle-
rosis and white matter change. However, Binswanger disease
and CAA are now often regarded as part of the same spec-
trum disease; the former labeled type 1 and the latter type 2
small vessel disease (Pantoni, 2010). Both types of arteriopathies
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make dementia patients vulnerable to hemodynamic fluctua-
tion through impairments in cerebral autoregulation and vas-
cular reactivity (Tanoi et al., 2000; Pimentel-Coelho and Rivest,
2012). Consequently, hypoperfusion induces Aβ overproduction
and elimination failure (Zlokovic, 2011; Carare et al., 2013; Elali
et al., 2013). Brain ischemia and hypoxia modulates amyloid pre-
cursor protein (APP) cleavage enzymes such as β-secretase and
γ-secretase, thereby resulting in increased Aβ production (Sun
et al., 2006; Guglielmotto et al., 2009; Kitaguchi et al., 2009; Li
et al., 2009). Excess Aβ contributes to the impairment of Aβ clear-
ance and CAA (Joachim et al., 1989; Rovelet-Lecrux et al., 2006;
Han et al., 2008). Aβ elimination failure could also result from
arteriolosclerosis (Weller et al., 2009). Thus, dementia patients
with a single simple etiology are scarcely seen, except for juve-
nile familial AD cases caused by mutations in the APP or pre-
senilin genes, comprising <1% of AD cases (Campion et al.,
1999).
In order to explore novel therapies in AD, we must consider
the “AD malignant cycle” (Figure 1). In this scheme, cessation
of Aβ overproduction is not sufficient to treat patients with spo-
radic AD, and important components of the cycle, brain ischemia,
and CAA should also be noted. Insufficient Aβ clearance seems to
be more crucial than Aβ overproduction in sporadic AD patients
(Mawuenyega et al., 2010). Even in familial AD cases, the onset of
dementia is often delayed until the fifth or sixth decade, suggesting
that the aging-associated failure in clearance also plays a part in the
pathogenesis of inherited types of the disease (Weller et al., 2008).
Therefore, recent work has focused on the failure of Aβ elimi-
nation as the most important therapeutic targets and adopted a
“neurovascular” approach as a strategy to tackle AD (Vardy et al.,
2005; Deane et al., 2008; Carare et al., 2013).
This review mainly focuses on the mechanisms of Aβ elimi-
nation and the drug development to facilitate Aβ clearance. The
perivascular lymphatic drainage system, one of the Aβ clearance
mechanisms, is closely associated with AD and CAA (Carare et al.,
2013). In addition, the possibility of drugs enhancing perivascular
drainage as well as future strategies for AD and CAA treatment
will be reviewed.
Aβ CLEARANCE: 3-d MECHANISM
So far, several mechanisms of eliminating Aβ proteins have been





Aβ catabolism is regulated by a series of degrading enzymes as
well as glial cells, such as astrocytes and microglia, in the brain
parenchyma (Vardy et al., 2005). Among them, neprilysin has
received much attention (Iwata et al., 2000). Previous reports
have described impaired Aβ degradation in neprilysin-deficient
mice (Iwata et al., 2001) and amelioration of Aβ pathology in
APP-transgenic mice, when injected with viral vector expressing
human neprilysin gene (Marr et al., 2003; Iwata et al., 2004, 2013).
Levels of neprilysin mRNA were found to be significantly lower
in the hippocampus and middle temporal gyrus of AD brains
compared with normal control patients (Yasojima et al., 2001).
Decreased neprilysin activity was also associated with CAA (Min-
ers et al., 2006). Thus, the up-regulation of cerebral neprilysin
FIGURE 1 | “AD malignant cycle”. Aβ overproduction impairs Aβ elimination leading to vascular smooth muscle cells (vSMC) degeneration, cerebral ischemia,
and microinfarcts. Ischemia also induces Aβ overproduction. Such vicious circle consists of core pathology in sporadic AD. Note that cessation of Aβ
overproduction is not sufficient to sever the cycle.

























































Saito and Ihara New therapeutic approaches for CAA
FIGURE 2 | Aβ clearance: 3-d mechanism. Aβ is mainly eliminated by the following mechanisms: (1) enzymatic/glial degradation, (2) transcytotic delivery, and
(3) perivascular drainage.
activity could potentially be targeted in the treatment of AD.
Indeed, a somatostatin receptor agonist has recently been shown
to increase neprilysin activity and decrease Aβ levels in senescence-
accelerated mice (Sandoval et al., 2012). However, Meilandt et al.
reported that an 11-fold greater neprilysin overexpression failed
to reduce pathogenic Aβ oligomers and improve deficits in spa-
tial learning and memory in AD model mice (Meilandt et al.,
2009). It was also reported that cerebral Aβ concentration was too
low to be degraded by neprilysin (Shibata et al., 2000). The affin-
ity of neprilysin for its physiological substrates (e.g., enkephalins,
tachykinins, atrial natriuretic peptide) is within the millimolar
range (Hersh and Morihara, 1986), while the levels of Aβ in the
brain are normally in the nanomolar range and up to 1µM/kg
even in APP-transgenic mice (Hsiao et al., 1996). Thus, only small
concentrations of Aβ will likely bind to neprilysin under physio-
logical and pathological conditions. Many issues should be solved
to proceed to drug development of neprilysin activators.
Angiotensin-converting enzyme (ACE) is another Aβ-
degrading agent. Captopril, a blood–brain barrier (BBB) penetrat-
ing ACE inhibitor, increases Aβ accumulation (Zou et al., 2007),
and ACE overexpression in myelomonocytes reduces Aβ deposi-
tion in AD model mice (Bernstein et al., 2014). However, brain
ACE deficient mice showed no significant alteration in endoge-
nous Aβ levels (Eckman et al., 2006). In addition, two small studies
assessing the clinical use of ACE inhibitors, found that they did not
deteriorate dementia in AD and amnestic mild cognitive impair-
ment (MCI) patients (Ohrui et al., 2004; Rozzini et al., 2006).
Because of such conflicting findings, contributions of ACE to Aβ
degradation in the brain per se remain ambiguous.
Insulin-degrading enzyme (IDE) is also known to have Aβ-
degrading properties, and hyperinsulinemia in diabetes mellitus
competitively inhibits Aβ degradation (Craft and Watson, 2004;
Qiu and Folstein, 2006). Indeed, IDE deficient mice demonstrate
increased cerebral accumulation of endogenous Aβ with hyperin-
sulinemia and glucose intolerance (Farris et al., 2003), and IDE
overexpression ameliorates Aβ pathology (Leissring et al., 2003),
suggesting a link between insulin metabolism and Aβ degradation.
However, clinical evidence is still lacking and further studies on the
association of IDE with AD pathogenesis may uncover potential
treatment targets in AD. Some researchers have labeled AD “type
3 diabetes” (de la Monte and Wands, 2008). If hyperinsulinemia is
related to resistance of neuronal cells to insulin, impaired insulin
signaling in neurons is thought to lead to neuronal disturbances. A
clinical trial assessing intranasal insulin therapy in the treatment
of AD and amnestic MCI is anticipated to further elaborate on
the relationship between AD and insulin signaling (Craft et al.,
2012).
TRANSCYTOTIC DELIVERY
The cerebral vasculature originates from large arteries, such as
middle cerebral artery and the circle of Willis. These arteries
branch into the leptomeningeal arteries, which travel on the sur-
face of the brain in the subarachnoid space. Leptomeningeal
arteries further branch into smaller arteries and arterioles con-
sisting of three layers: tunica intima (endothelium), tunica media
(smooth muscle cells), and tunica adventitia (mainly collagen
fibers). Finally, the terminals of arterioles become capillaries. Cap-
illary lumen and brain parenchyma are separated by the BBB,
which prevents the passive exchange of solutes between blood and
brain (Iadecola, 2004).
Lipoprotein receptor-related protein-1 (LRP-1), a multifunc-
tional scavenger and signaling receptor, is expressed in neural
cells and cerebral microvessels including capillaries, small venules,
and arterioles (Wolf et al., 1992; Tooyama et al., 1995; Shibata
et al., 2000). LRP-1 has received increasing attention as it medi-
ates transport of Aβ out of the brain across the BBB (Bell and
Zlokovic, 2009). Many reports have described the genetic link-
age of LRP-1 with AD (Kang et al., 1997; Lambert et al., 1998;
Wavrant-DeVrièze et al., 1999) and CAA (Christoforidis et al.,
2005). Colocalization of LRP-1 with Aβ was pathologically recog-
nized in senile plaques (Rebeck et al., 1993; Donahue et al., 2006),
strengthening the linkage. The relationship is further supported
by reduced LRP-1 staining in vessels both in AD patients (Shibata
et al., 2000; Donahue et al., 2006) and CAA model mice carrying a
vasculotropic Dutch/Iowa mutant form of APP gene (Deane et al.,
2004).
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Animal experiments have confirmed the importance of tran-
scytosis in the regulation of cerebral Aβ levels. Five hours after
microinjection of 125I-labeled Aβ1–40 into the caudate nucleus,
73.8% of labeled tracer had been found in blood across the BBB in
young wild-type mice, while 125I-labeled Aβ1–40 in cerebrospinal
fluid (CSF) measured 10.7%, and only 15.6% of the dose remained
in the brain parenchyma (Shibata et al., 2000). These findings sug-
gest that endothelial transcytosis by LRP-1 and others is probably
one of the most prominent pathways in cerebral Aβ clearance,
although this study might underestimate other clearance path-
ways as all the Aβ peptides found in blood are considered to derive
from transcytotic delivery.
LRP-1 binds to Aβ directly (Deane et al., 2004), but also binds
indirectly via its ligands including α2-macroglobulin, receptor-
associated protein, and apolipoprotein E (ApoE) (Narita et al.,
1997; Bu, 2009; Kanekiyo and Bu, 2009). ApoE is the main chap-
erone of Aβ in central nervous system (Holtzman et al., 2012;
Zolezzi et al., 2014). To date, three isoforms of ApoE have been
described (ε2, ε3, and ε4), and the ApoE ε4 variant is considered to
be one of the most relevant risk factors for AD and CAA (Premku-
mar et al., 1996; Zolezzi et al., 2014). ApoE immunoreactivity is
common in amyloid plaques, suggesting that ApoE interacts with
Aβ directly in AD brains and could strongly influence the rate of
Aβ removal (Namba et al., 1991; Holtzman et al., 2012). Several
authors have proposed ApoE as therapeutic target for Aβ clear-
ance (Cramer et al., 2012; Zolezzi and Inestrosa, 2014). Cramer
et al. reported that bexarotene, a retinoid X receptor agonist, stim-
ulated the ApoE-dependent Aβ clearance through the actions of
liver X receptors and peroxisome proliferator-activated nuclear
receptor gamma in AD model mice (Cramer et al., 2012). As a
result, cognitive deficits improved with reduced burden of Aβ
plaque. However, some conflicting reports have been also doc-
umented (Fitz et al., 2013; Price et al., 2013; Tesseur et al., 2013;
Veeraraghavalu et al., 2013). Further analysis and experimentation
should be performed.
Receptor for advanced glycation end products (RAGE), an
immunoglobulin supergene family member, is also known to be
a key molecule in Aβ transcytosis (Yan et al., 2012). Strong stain-
ing for RAGE has been reported in the vessels of AD patients
(Yan et al., 1996; Donahue et al., 2006) and has been shown to
mediate influx of circulating Aβ into brain across the BBB (Deane
et al., 2003). In addition, RAGE contributes to Aβ-related synap-
tic dysfunction and microglial activation (Yan et al., 1996; Origlia
et al., 2008, 2010). These findings suggest that RAGE could be
a therapeutic target in AD and CAA. Indeed, a RAGE inhibitor
ameliorated cerebral Aβ burden and normalized cognitive perfor-
mance in APP-transgenic mice (Deane et al., 2012). The phase
III 18 month clinical trial of the RAGE inhibitor TTP488 is being
planned for mild to moderate AD patients (The U.S. National
Institutes of Health, 2014); positive results in phase II testing have
been reported (Burstein et al., 2014).
PERIVASCULAR DRAINAGE
The central nervous system is devoid of conventional lymphatic
vessels, unlike other organs containing networks of lymphatic
vessels, which process various substances, such as wastes, fluid,
proteins, and cells from tissues to lymph nodes. However, the
lymphatic perivascular drainage system in the brain performs the
main function assigned to systemic lymphatic vessels. Analysis
of the lymphatic perivascular drainage system dates back as far
as the nineteenth century, where it was shown that Indian ink
injected into cisterna magna drained to the cervical lymph nodes
(Schwalbe, 1869; Weller et al., 2010).
The detail of perivascular drainage system has been exam-
ined mainly by intracranial injection of various tracers, including
125I-labeled albumin (Bradbury et al., 1981; Szentistványi et al.,
1984; Yamada et al., 1991), Indian ink (Zhang et al., 1992), and
various fluorescent tracers (Carare et al., 2008). Recently, this
drainage pathway was also confirmed by multi-photon imaging
(Arbel-Ornath et al., 2013).
Fluorescent tracers, injected to the striatum, spread diffusely
through the extracellular spaces of the brain parenchyma and
enter the walls of blood vessels almost immediately. Confocal
microscopy showed tracers colocalize with laminin in the base-
ment membranes of capillary walls. Injected tracers were cleared
from the basement membranes in the walls of capillaries and arter-
ies, while some tracers were taken up by smooth muscle cells and
perivascular macrophages (Zhang et al., 1992; Carare et al., 2008).
Studies using radiolabeled tracers showed that drainage of inter-
stitial fluid (ISF) and solutes continues along tunica media and
the tunica adventitia of leptomeningeal and major cerebral arter-
ies, through the base of the skull to the deep cervical lymph nodes
(Szentistványi et al., 1984; Weller et al., 2010). Tissue soluble Aβ
was detected by enzyme immunoassay in meningeal arteries and
intracranial arteries but not in extracranial vessels (Shinkai et al.,
1995). The clearance system leading to cervical lymph nodes was
confirmed by subsequent injection into the inferior colliculus (Ball
et al., 2010). Theoretical models have indicated that arterial pul-
sations could be the motive force behind ISF and solutes being
driven centrifugally from the brain by reflection waves that follow
each cardiac pulse wave (Schley et al., 2006).
This drainage route closely corresponds with the distribution
of Aβ in the basement membranes of capillary and artery walls
in CAA (Weller et al., 1998), which implies that the congestion
of drainage pathway is associated with the pathogenesis of CAA.
The fact that CAA was accelerated in the brains of immunized
AD patients and that the CSF Aβ concentration was decreased
both in AD and CAA patients may result from an impaired
perivascular drainage pathway (Nicoll et al., 2004; Patton et al.,
2006; Verbeek et al., 2009). Consistent with this, perivascular
drainage of solutes is impaired in the aging mouse brain and in
the presence of CAA (Hawkes et al., 2011). The fact that cerebral
Aβ clearance was delayed after photothrombosis within individ-
ual vessels or middle cerebral artery occlusion (Garcia-Alloza
et al., 2011), and after bilateral common carotid artery stenosis
(Okamoto et al., 2012), further supports the notion that brain
ischemia and impaired arterial pulsation could be an exacerba-
tion factor of CAA. Consistent with the experimental data is the
clinical finding that arterial stiffness, indicated by pulse wave
velocity, has been associated with Aβ deposition in the brains
of non-demented elderly adults (Hughes et al., 2013). There-
fore, vasoactive drugs could have potential in the improvement
of lymphatic congestion and facilitation of Aβ clearance in the
brain.
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CONVINCING EFFECTS OF PHOSPHODIESTERASE INHIBITOR
Among varieties of vasoactive drugs, cilostazol, a selective inhibitor
of type 3 phosphodiesterase (PDE), is likely to be a promising agent
for AD and CAA (Figure 3). PDE3 can hydrolyze both cAMP and
cGMP, while increasing cAMP level is a major pharmacological
effect of cilostazol (Ikeda, 1999). PDE3 is widely expressed in
central nervous system and up-regulated in Aβ-positive vessels,
especially in vascular smooth muscle cells (vSMC) (Maki et al.,
2014), suggesting the possibility that PDE3 inhibition could be
therapeutic for CAA. Cilostazol possesses multiple effects, such as
increasing pulse rate (Shinohara et al., 2010) and arterial elastic-
ity (Han et al., 2013), prolonging pulse duration time (Aruna and
Naidu, 2007), and dilating cerebral vessels (Tanaka et al., 1989; Birk
et al., 2004a,b); such vasoactive actions may promote efficiency of
perivascular drainage. In support of this, clearance of fluorescent
soluble Aβ tracers is significantly enhanced in cilostazol-treated
CAA model mice, thereby resulting in maintenance of vascular
integrity, amelioration of Aβ deposits (Figure 4), and prevention
of cognitive decline (Maki et al., 2014). Memory-preserving activ-
ity of cilostazol has been demonstrated in aged wild-type mice
(Yanai et al., 2014) and a rat model of chronic cerebral hypoper-
fusion (Watanabe et al., 2006), suggesting that cilostazol could be
a potential disease modifying therapy of AD and other dementing
disorders.
Recently, Nedergaad et al. suggested the “glymphatic path-
way,” consisting of para-arterial CSF influx route, para-venous
ISF efflux route, and convective bulk fluid flux (Iliff and Ned-
ergaard, 2013; Nedergaard, 2013), as another clearance system in
central nervous system. Aβ proteins may be cleared through this
perivascular pathway, as well as the perivascular drainage system
(Iliff et al., 2012), although the relationship to CAA pathogen-
esis remains to be clarified as Aβ does not accumulate in the
venous system. Cerebral arterial pulsation with a vasoactive agent
dobutamine drives perivascular CSF–ISF exchange (Iliff et al.,
FIGURE 3 | Cilostazol with 3 Arrows: triple effects toward potential resolution of dementia. Cilostazol, a selective inhibitor of PDE3, has pleiotropic
capabilities of suppressing Aβ production in neurons, enhancing Aβ clearance through perivascular drainage system, and inhibiting platelet aggregation
(anti-platelet effects).
FIGURE 4 | Cilostazol reduced Aβ deposition. Hippocampal images
obtained from 17-month-old homozygous Tg-SwDI mice, a model of CAA,
treated with vehicle (A,B) or cilostazol (C) for 15 months show that cilostazol
treatment reduced levels of Aβ deposits in the hippocampus compared with
vehicle treatment. Scale bars indicate 100µm. (A) HE staining. (B,C)
Thioflavin-S staining.
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2013). Further investigation is required to determine whether
other vasoactive drugs such as cilostazol could have a potential
to facilitate paravascular clearance.
Many inhibitors of other PDE subtypes have been reported
to produce cognitive enhancement (Reneerkens et al., 2009) and
have been associated with neuronal cAMP signaling activation.
Rolipram, a PDE4 inhibitor, reverses the decrease in cAMP regu-
latory element-binding protein (CREB) phosphorylation, which
results in persistent improvement in synaptic function in AD
model mice (Gong et al., 2004). Sildenafil, a PDE5 inhibitor,
decreases Aβ levels in extracts of cerebral cortex and improves
associative and spatial memory in AD model mice (Puzzo et al.,
2009). Caffeine is a non-specific PDE inhibitor (Yoshimura, 2005),
and its beneficial effects have been clarified in many clinical AD
studies (Eskelinen et al., 2009; Eskelinen and Kivipelto, 2010).
Caffeine stimulates cAMP-dependent protein kinase A signaling
and increases CREB phosphorylation in AD model mice (Aren-
dash et al., 2006; Zeitlin et al., 2011). Protein kinase A activation
then suppresses the expression of Aβ-synthesizing enzymes such
as β- and γ-secretase, leading to reduced Aβ production (Aren-
dash et al., 2009). Cilostazol also reduces Aβ production in vitro
(Lee et al., 2012, 2014; Maki et al., 2014), and suppresses Aβ-
induced tauopathy and tau phosphorylation in vitro (Lee et al.,
2012, 2014). However, as only a minor fraction of cilostazol
passes through BBB (Akiyama et al., 1985), it remains to be eluci-
dated whether these positive effects of cilostazol do occur in AD
patients.
Cilostazol has a wide variety of pleiotropic effects capable of
inducing neurogenesis (Lee et al., 2009; Tanaka et al., 2010), pro-
moting oligodendrocyte precursor cell differentiation (Miyamoto
et al., 2013), preventing lipid peroxidation (Hiramatsu et al.,
2010; Kurtoglu et al., 2014), enhancing cholesterol efflux from
macrophages (Nakaya et al., 2010), ameliorating insulin resis-
tance (Wada et al., 2013), reducing inflammatory burden (Otsuki
et al., 2001; Tsai et al., 2008; Hattori et al., 2009), and improving
systemic lymphatic function by inducing proliferation and stabi-
lization of lymphatic endothelial cells (Kimura et al., 2014). In
a clinical setting, cilostazol is currently used as an anti-platelet
drug (Gotoh et al., 2000; Shinohara et al., 2010), and may be
used to prevent ischemic events in patients with CAA. Major
manifestations of CAA include lobar hemorrhage and cortical
microhemorrhage, as well as CMI. As most CAA patients are
elderly (Zhang-Nunes et al., 2006), this necessitates the use of anti-
platelet drugs with little risk of hemorrhage (Charidimou et al.,
2012). The second Cilostazol Stroke Prevention Study (CSPS2)
for patients with cerebral infarction showed that the hemorrhagic
stroke was significantly less frequent in cilostazol treatment than
with aspirin (Shinohara et al., 2010; Uchiyama et al., 2014). The
prevention of cerebral hemorrhage may be explained by repro-
ducible experimental evidence showing that cilostazol inhibits
expression of matrix metalloproteinase-9 and protects vascular
endothelial cells (Ishiguro et al., 2010; Hase et al., 2012; Kasa-
hara et al., 2012). Endothelial protection with cilostazol medi-
ates increase in nitric oxide, which dilates blood vessels (Oyama
et al., 2011), leading to increased cerebral blood flow (Mochizuki
et al., 2001; Matsumoto et al., 2011; Sakurai et al., 2013). These
results suggest that cilostazol could be suitable for patients with
both AD and CVD, the most common type of dementia in the
elderly.
Favorable effects have already been described in observational
clinical studies, which demonstrated the efficacy of cilostazol
in patients with MCI (Taguchi et al., 2013), donepezil-treated
patients with clinically probable AD (Arai and Takahashi, 2009;
Ihara et al., 2014), and AD with CVD (Sakurai et al., 2013). Ran-
domized placebo-controlled clinical trials are being planned for
patients with MCI.
FUTURE STRATEGY FOR AD AND CAA TREATMENT
Aging inevitably increases the amount of Aβ burden in the brain,
implying a strong relationship between impaired Aβ metabolism
and age (Funato et al., 1998). Since heterogeneity and multimor-
bidity are common in the elderly (Barnett et al., 2012), dementia
likely originates from a combination of different pathological sub-
strates. As the population ages, the distribution of AD shifts to
older ages in developed countries (Hebert et al., 2013), resulting
in an increasing number of demented patients with numerous
complicated etiologies. Given that the balance between Aβ synthe-
sis and clearance determines brain Aβ accumulation, and that Aβ
is cleared by several pathways stated above, multi-drugs combi-
nation therapy would likely be necessary for sporadic AD with
complicated etiologies. Combination therapy has already been
applied to various diseases, such as hypertension, diabetes mel-
litus, and malignant tumors. The ultimate goal will be to develop
a sovereign remedy of AD, and we hope that the recent rapid
advances in drug development will enable us to delay the onset
or modify the progression of cognitive impairment with multi-
targeting therapies. Further investigation from various viewpoints
will thus be essential for the development of novel treatment for
AD and CAA.
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